---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-169947"
form_type: "8-K"
ticker: "INDV"
cik: "0001625297"
company_name: "Indivior Pharmaceuticals, Inc."
filed_at: "2025-07-31T23:59:59+00:00"
generated_at: "2026-05-17T22:20:02.526590+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Indivior raises FY 2025 guidance after Q2 beat; SUBLOCADE revenue up 9%

## Summary
- Q2 total net revenue $302M (+1% YoY); net income $18M ($0.14 EPS); non-GAAP diluted EPS $0.51.
- SUBLOCADE net revenue $209M (+9% YoY, +19% vs Q1'25); U.S. SUBLOCADE $195M (+9% YoY).
- FY 2025 guidance raised: net revenue $1.03B-$1.08B (prior $955M-$1.025B); adjusted EBITDA $275M-$300M (prior $220M-$260M).
- Adjusted EBITDA Q2 $88M vs $93M Q2'24; cash and investments $538M at Q2 end.

## SEC filing metadata
- accession: 0001193125-25-169947
- form_type: 8-K
- ticker: INDV
- cik: 0001625297
- company_name: Indivior Pharmaceuticals, Inc.
- filed_at: 2025-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625297/000119312525169947/0001193125-25-169947-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625297/000119312525169947/d908304d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-169947
- JSON: https://secwatch.observer/filing/0001193125-25-169947.json
- Plain text: https://secwatch.observer/filing/0001193125-25-169947.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.